Metastatic Breast Cancer: Bevacizumab Slows Progression, But Has No Impact On Surviva

[News]

The cancer drug bevacizumab (Avastin®) offers only a modest benefit in prolonging disease progression in patients with advanced stage breast cancer, according to a systematic review by Cochrane researchers...

More... (http://www.medicalnewstoday.com/releases/247712.php)